Abstract
This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have